Abstract
Three novel complexes have been prepared through reactions of precursor [(dmso)2H][trans-RuCl4(dmso-S)2] (P) and 1,10-phenanthroline (phen) at different conditions. Whereas the analogs of mer-[RuCl3(dmso-S)(phen)] (1) and [Ru(phen)3]Cl2·6CH3OH (3·6CH3OH) have already been prepared by other synthetic routes before, product (H3O)[RuCl4(phen)]·4H2O (2·4H2O) is unprecedented. In the latter, isolated from highly acidic medium, one strongly bound dmso molecule in precursor P was substituted by chloride. Biological activity of 1 and previously isolated ruthenium-purine complexes ([mer-RuCl3(dmso-S)(acv)(CH3OH)] (4) (acv = acyclovir); [trans-RuCl4(dmso-S)(guaH)] (5) (guaH = protonated guanine)) was tested and compared. These data show that compounds 1, 4 and 5 are slightly cytotoxic against B-16 malignant melanoma cells but not against non-transformed V-79-379A cells. It seems that coordinated phen ligand increases the cytotoxicity of 1 in comparison to ruthenium precursor. The inability of tested compounds to induce lysis of bovine erythrocytes suggests that their cytotoxic effect is not due to the membrane damage.
Highlights
Diffraction data for all three compounds were collected on a Nonius Kappa CCD diffractometer with graphite monochromated MoKα radiation at temperature 150 K
Structures were solved by direct methods using SIR972
Most of the positions of hydrogen atoms were obtained from the difference Fourier maps, the remaining were calculated
Summary
Diffraction data for all three compounds were collected on a Nonius Kappa CCD diffractometer with graphite monochromated MoKα radiation at temperature 150 K. Iztok Turela*, Amalija Golobiča, Jakob Kljuna, Petra Samastura, Urška Batistab, Kristina Sepčićc A Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI1000 Ljubljana, Slovenia. B Institute of Biophysics, Faculty of Medicine, University of Ljubljana, Lipičeva 2, 1000 Slovenia c Biotechnical Faculty, Department of Biology, University of Ljubljana, Večna pot 111, 1000
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
